Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes

Response to consensus statement

  1. Leslie Citrome, MD, MPH and
  2. Jan Volavka, MD, PHD
  1. Clinical Research and Evaluation Facility, Nathan S. Kline Institute for Psychiatric Research, New York University School of Medicine, New York, New York
  1. Address correspondence to Dr. Leslie Citrome, New York University School of Medicine, Nathan S. Kline Institute for Psychiatric Research, Clinical Research and Evaluation Facility, Orangeburg, NY 10962. E-mail: citrome{at}nki.rfmh.org

The report from the Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes Consensus Panel (1) contains valuable advice for the appropriate and prudent monitoring of patients who are at risk for type 2 diabetes. The recommendations made are similar to a prior consensus conference (2) and, if they are followed, will benefit our vulnerable patients by the early identification and treatment of metabolic disorders.

However, the report probably overreaches available evidence when suggesting that clinicians should consider prescribing one antipsychotic over another with the aim of avoiding diabetes. Although clear differences exist in liability for weight gain (and consequently dyslipidemias), quantifiable risk differences among …

| Table of Contents